Ocean Biomedical, Inc.(OCEA)Earnings, Financials & Key Ratios

OCEA•NASDAQ

$0.00

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryDrug Discovery and Antibody Platforms

AboutOcean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.Show more

Revenue$0
EBITDA$0+100.0%
Net Income-$3M-683.8%
EPS (Diluted)-0.12-153.2%
ROE-98.81%-18408.4%

OCEA Price & Volume

Ocean Biomedical, Inc. (OCEA) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Absence Masks Deep Liquidity Risks

Investment Thesis • Updated 2025Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Capital Access and Dilution

Key Thesis Takeaways

Ocean Biomedical remains a high-risk, pre-clinical entity characterized by a total absence of commercial revenue and a deteriorating equity position of negative $92.4 million as of 2025Q1.
The company's reliance on dilutive financing to sustain operations, coupled with erratic R&D spending that dropped to $18,000 in 2025Q1, suggests significant uncertainty regarding its ability to reach clinical milestones.
Investors should exercise extreme caution given the precarious current ratio of 0.06 and the historical volatility of net income, which has been heavily influenced by non-operating accounting adjustments.

Verdict Logic

the company's precarious financial health is highlighted by a current ratio of 0.06 and a persistent lack of revenue, which necessitates ongoing reliance on dilutive capital raises to fund operations.

OCEA Growth Metrics

Ocean Biomedical, Inc. (OCEA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM0.82%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM3.45%

Return on Capital

10 Years-1.68%

5 Years-1.68%

3 Years-1.68%

Last Year-

Peers Comparison

Key metrics vs top competitors for Ocean Biomedical, Inc. (OCEA)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
OCEAOcean Biomedical, Inc.Current	$0.00	$8.25K	-0.00	—	—	-98.81%	—
IMVTImmunovant, Inc.	$40.09	$8.23B	-14.47	—	—	-68.16%	—
KALAKALA BIO, Inc.	$1.51	$33.11M	-0.46	—	—	-1335.64%	—
AGENAgenus Inc.	$3.50	$145.75M	-1029.41	10.37%	52.16%	—	—
TPVGTriplePoint Venture Growth BDC Corp.	$4.75	$192.85M	3.89	36.55%	-19.55%	-3.39%	—
NUVBNuvation Bio Inc.	$5.67	$1.97B	-9.45	698.96%	-102.06%	-44.1%	—